OMass Therapeutics
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
The Schrodinger Building, The Oxford Sci...Phone Number
+44 1865548350Website
www.omass.comRevenue
$9.2 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About OMass Therapeutics
OMass Therapeutics is a private biotechnology company that specializes in drug discovery and technology. The company was founded in 2016 and is headquartered in Oxford, England.Explore more
OMass Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OMass Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if OMass Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when OMass Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Check out if OMass Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at OMass Therapeutics
Click to see if OMass Therapeutics had a recent Job posting/layoffs
OMass Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on OMass Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once OMass Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined OMass Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to OMass Therapeutics
Compare insights from companies similar to OMass Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
OMass Therapeutics
$9.2M
11-50
Private
$145.6M
2016
PK
Parth KapoorProtein Biochemist and Mass Spec- Senior Scientist
Company Profile Activity
Activity Insights
OMass Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
OMass Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about OMass Therapeutics.
OMass Therapeutics financials insights
Gather financial insights about OMass Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Angel/Seed
$9.9M
2020
Series A
$35.8M
2022
Series B
$100M
OMass Therapeutics Tech Stack
A closer look at the technologies used by OMass Therapeutics
See more technologies
Most Recent Scoops
Partnership
Partnership, Product Management, Omnichannel, Pharmaceuticals, Channel Sales
Event
Product Marketing, Events, Engineering, Product Management, Sales, Logistics / Supply Chain, Laboratory Operations, Chemical Engineering, Field /Outside Sales, Field Marketing, Manufacturing Operations, Operations
Open Position
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
OMass Therapeutics News & Media
OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease
Oxford, United Kingdom – 2nd September 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that it has entered into an exclusive collaboration and license agreement with Genentech, a member of the Roche Group, for the rights to develop and commercialize OMass’ preclinical oral small molecule program for inflammatory bowel disease.OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025
Oxford, United Kingdom – 7th July 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that preclinical data for OMS1620, it’s lead program targeting the melanocortin-2 (MC2) receptor, will be presented at ENDO 2025, the Annual Endocrine Society Meeting, taking place in San Francisco from 12-15 July.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OMass Therapeutics
Sign Up For FreeTo access detailed company insights
OMass Therapeutics is a private biotechnology company that specializes in drug discovery and technology. The company was founded in 2016 and is headquartered in Oxford, England.... Read More
